A Randomized Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI) - Bronson Healthcare

Intrepid Traumatic Brain Injury

A Randomized Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI)

Objective

Moderate to severe traumatic brain injury frequently results in persistent problems with memory, attention span, mood and more complex brain functioning such as planning and organizing. There are currently no drugs available to reduce the brain damage or the persisting symptoms that result from TBI. The longer term goal of this study is to provide physicians with a safe and effective treatment for TBI.

Eligible patients must be between 16 and 75 years of age admitted to the hospital with moderately severe head injury.

ClinicalTrials.Gov Number
NCT00805818
Principal Investigator(s)
Jon Walsh, MD
Sponsor(s)
Neuren Pharmaceuticals Inc.
Contact
Brianna Johnson, BS, CCRC at 269-341-8410
or johnsobr@bronsonhg.com
How to Participate

Subjects will be randomly assigned to one of three doses of drug or placebo and will be evaluated for safety and effectiveness. Approximately 260 patients will enroll in the study at multiple locations. More information can be found here.

Location

  • Bronson Methodist Hospital
    601 John St.
    Kalamazoo, MI 49007
    Main: 269-341-7654